Novavax vaccine now available to order 

July 26, 2022

The Centers for Disease Control and Prevention (CDC) has endorsed the Advisory Committee on Immunization Practices (ACIP)’s recommendation of Novavax COVID-19 vaccine as a two-dose primary series vaccination in adults ages 18 and older. This includes individuals who are moderately or severely immunocompromised.

Novavax is the first COVID-19 protein subunit vaccine that the CDC has recommended for use in the United States. There are now multiple types of COVID-19 vaccines available in the U.S., offering more options and flexibility for the public, as well as vaccine providers.

Due to the limited supply available, the maximum order in ImmPact will be 200 doses per request. We encourage providers to administer Novavax only to patients who are unable to receive an mRNA COVID-19 vaccine.

Recommendations:

• 2 doses in the primary series, given 3–8 weeks apart.
• People who are moderately or severely immunocompromised should also receive 2 doses, given 3 weeks apart (a 3rd primary dose is not currently authorized).
• Novavax COVID-19 vaccine is not authorized for use as a booster dose.

Resources:

• Updated Interim Clinical Considerations
• Updated web pages for the public including:
  • Novavax COVID-19 Vaccine Overview and Safety | CDC
  • Understanding Protein Subunit COVID-19 Vaccines
  • Stay Up to Date with Your COVID-19 Vaccines | CDC
  • COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised | CDC
• Updated CDC COVID-19 booster tool
• Clinician Outreach and Communication Activity (COCA) call – Thursday, July 28 from 2:00 pm - 3:00 pm ET .

If you have any questions, please contact the Maine Immunization Program at (207) 287-3746 or email ImmunizeME.DHHS@maine.gov.